207 related articles for article (PubMed ID: 16113546)
1. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial.
Scholten T; Dekkers CP; Schütze K; Körner T; Bohuschke M; Gatz G
Digestion; 2005; 72(2-3):76-85. PubMed ID: 16113546
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
3. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease.
Kaspari S; Kupcinskas L; Heinze H; Berghöfer P
Eur J Gastroenterol Hepatol; 2005 Sep; 17(9):935-41. PubMed ID: 16093871
[TBL] [Abstract][Full Text] [Related]
4. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
5. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Bochenek WJ; Mack ME; Fraga PD; Metz DC
Aliment Pharmacol Ther; 2004 Nov; 20(10):1105-14. PubMed ID: 15569113
[TBL] [Abstract][Full Text] [Related]
6. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
Richter JE; Bochenek W
Am J Gastroenterol; 2000 Nov; 95(11):3071-80. PubMed ID: 11095320
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
Wo JM; Koopman J; Harrell SP; Parker K; Winstead W; Lentsch E
Am J Gastroenterol; 2006 Sep; 101(9):1972-8; quiz 2169. PubMed ID: 16968502
[TBL] [Abstract][Full Text] [Related]
8. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
9. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Bytzer P; Blum A; De Herdt D; Dubois D;
Aliment Pharmacol Ther; 2004 Jul; 20(2):181-8. PubMed ID: 15233698
[TBL] [Abstract][Full Text] [Related]
10. Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Dupas JL; Houcke P; Samoyeau R;
Gastroenterol Clin Biol; 2001 Mar; 25(3):245-50. PubMed ID: 11395670
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole versus pantoprazole for healing erosive oesophagitis.
Vcev A; Begić I; Ostojić R; Jurcić D; Bozić D; Soldo I; Gmajnić R; Kondza G; Khaznadar E; Mićunović N
Coll Antropol; 2006 Sep; 30(3):519-22. PubMed ID: 17058517
[TBL] [Abstract][Full Text] [Related]
12. Prevention of erosive oesophagitis relapse with pantoprazole.
Richter JE; Fraga P; Mack M; Sabesin SM; Bochenek W;
Aliment Pharmacol Ther; 2004 Sep; 20(5):567-75. PubMed ID: 15339328
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.
Madan K; Ahuja V; Kashyap PC; Sharma MP
Dis Esophagus; 2004; 17(4):274-8. PubMed ID: 15569362
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
Tolia V; Bishop PR; Tsou VM; Gremse D; Soffer EF; Comer GM;
J Pediatr Gastroenterol Nutr; 2006 Apr; 42(4):384-91. PubMed ID: 16641576
[TBL] [Abstract][Full Text] [Related]
15. Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study.
Körner T; Schütze K; van Leendert RJ; Fumagalli I; Costa Neves B; Bohuschke M; Gatz G
Digestion; 2003; 67(1-2):6-13. PubMed ID: 12743434
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group.
Wurzer H; Schutze K; Bethke T; Fischer R; Luhmann R; Riesenhuber C
Hepatogastroenterology; 1999; 46(27):1809-15. PubMed ID: 10430350
[TBL] [Abstract][Full Text] [Related]
17. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease.
Scholten T; Teutsch I; Bohuschke M; Gatz G
Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101
[TBL] [Abstract][Full Text] [Related]
18. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
Digestion; 2005; 71(3):152-8. PubMed ID: 15870503
[TBL] [Abstract][Full Text] [Related]
19. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
20. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Regula J; Butruk E; Dekkers CP; de Boer SY; Raps D; Simon L; Terjung A; Thomas KB; Lühmann R; Fischer R
Am J Gastroenterol; 2006 Aug; 101(8):1747-55. PubMed ID: 16817839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
